In the past week, MRUS stock has gone up by 11.48%, with a monthly decline of -8.39% and a quarterly surge of 8.59%. The volatility ratio for the week is 4.97%, and the volatility levels for the last 30 days are 7.76% for Merus N.V The simple moving average for the last 20 days is 1.97% for MRUS’s stock, with a simple moving average of -9.38% for the last 200 days.
Is It Worth Investing in Merus N.V (NASDAQ: MRUS) Right Now?
The 36-month beta value for MRUS is at 0.94. Analysts have varying views on the stock, with 13 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MRUS is 61.26M, and currently, shorts hold a 12.11% of that float. The average trading volume for MRUS on April 18, 2025 was 692.05K shares.
MRUS) stock’s latest price update
The stock of Merus N.V (NASDAQ: MRUS) has increased by 2.73 when compared to last closing price of 41.91.Despite this, the company has seen a gain of 11.48% in its stock price over the last five trading days. seekingalpha.com reported 2025-04-07 that Merus stands out in biotech with its innovative Biclonics and Multiclonics platforms, focusing on bispecific and multispecific antibodies, particularly petosemtamab. Strong financials with $724 million cash runway through 2028, allowing strategic R&D investments without immediate capital market pressures. Petosemtamab shows robust clinical data, receiving two FDA Breakthrough Therapy designations, indicating significant potential in treating HNSCC and other cancers.
Analysts’ Opinion of MRUS
Many brokerage firms have already submitted their reports for MRUS stocks, with Piper Sandler repeating the rating for MRUS by listing it as a “Overweight.” The predicted price for MRUS in the upcoming period, according to Piper Sandler is $84 based on the research report published on February 13, 2025 of the current year 2025.
Wells Fargo, on the other hand, stated in their research note that they expect to see MRUS reach a price target of $91. The rating they have provided for MRUS stocks is “Overweight” according to the report published on February 07th, 2025.
Goldman gave a rating of “Buy” to MRUS, setting the target price at $73 in the report published on November 21st of the previous year.
MRUS Trading at -2.01% from the 50-Day Moving Average
After a stumble in the market that brought MRUS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.12% of loss for the given period.
Volatility was left at 7.76%, however, over the last 30 days, the volatility rate increased by 4.97%, as shares sank -10.88% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +3.35% upper at present.
During the last 5 trading sessions, MRUS rose by +11.48%, which changed the moving average for the period of 200-days by -20.93% in comparison to the 20-day moving average, which settled at $42.22. In addition, Merus N.V saw 2.39% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MRUS starting from Shuman Harry, who sale 4,000 shares at the price of $48.50 back on Mar 21 ’25. After this action, Shuman Harry now owns 11,002 shares of Merus N.V, valued at $193,990 using the latest closing price.
Shuman Harry, the VP Controller, PAO of Merus N.V, sale 2,500 shares at $54.00 during a trade that took place back on Aug 21 ’24, which means that Shuman Harry is holding 7,002 shares at $135,000 based on the most recent closing price.
Stock Fundamentals for MRUS
Current profitability levels for the company are sitting at:
- -7.53 for the present operating margin
- 0.98 for the gross margin
The net margin for Merus N.V stands at -5.96. The total capital return value is set at -0.39. Equity return is now at value -42.88, with -34.63 for asset returns.
Based on Merus N.V (MRUS), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -18.75.
Currently, EBITDA for the company is -269.6 million with net debt to EBITDA at 0.98. When we switch over and look at the enterprise to sales, we see a ratio of 74.48. The receivables turnover for the company is 7.67for trailing twelve months and the total asset turnover is 0.05. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.54.
Conclusion
In conclusion, Merus N.V (MRUS) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
